CompanyREVB REVBWNasdaqSan Diego, CA

Revelation Biosciences, Inc.

Revelation Biosciences develops Gemini, a proprietary formulation for rebalancing inflammation.

SEC EDGAR ClinicalTrials.gov revbiosciences.com

8-KAug 19Latest SEC filing, period to Aug 17

Aug 19Latest story

August 2026

Revelation Biosciences grants restricted stock to CEO and CFO tied to market cap goals

Aug 19PeopleRevelation Biosciences, Inc.

Revelation Biosciences reports Q2 2026 results, advances AKI trial prep

Aug 6Quarterly updateRevelation Biosciences, Inc.

July 2026

Revelation Biosciences adopts stockholder rights plan

Jul 13PeopleRevelation Biosciences, Inc.